Skip to content

Fetal focus: fetal intramuscular steroids for diabetic women at risk of preterm birth

Effect of fetal intramuscular steroids on maternal hyperglycaemia or ketoacidosis in diabetic women at risk of preterm birth

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616001577404
Enrollment
20
Registered
2016-11-15
Start date
2016-12-15
Completion date
2017-06-15
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Background: Administration of corticosteroids prior to birth is of clear benefit to the preterm neonate, with reductions in respiratory, neurological, gastrointestinal, and infectious morbidity, as well as decreased mortality. This benefit was previously proven to exist up to 34 weeks’ gestation but has recently been demonstrated to apply to all neonates born prior to 37 weeks. This benefit is not achieved without potential complications, however, including hyperglycaemia and ketoacidosis in diabetic mothers and neonatal hypoglycaemia. Direct fetal administration of corticosteroids, by ultrasound-guided intramuscular injection may provide the neonatal benefits of steroids while avoiding the maternal and neonatal complications. Objectives: This pilot study aims to assess the feasibility of a larger randomised controlled trial of direct fetal administration versus maternal administration of corticosteroids with the following objectives: a. To assess the effects of directly administered fetal corticosteroids upon maternal glucose homeostasis (hyperglycaemia and ketoacidosis). b. To demonstrate that direct administration of fetal corticosteroids is not associated with adverse fetal/neonatal outcomes including excess preterm birth or neurovascular injuries Trial plan: This pilot randomised controlled trial will recruit 20 pregnant women with pregestational type 1 or type 2 diabetes who are planned for delivery between 34+0 and 36+6 weeks’ gestation and therefore candidates for antenatal corticosteroid administration. Consenting women will be randomised to receive either standard maternal administration of two doses of betamethasone or direct fetal intramuscular injection of a single dose of betamethasone. The primary outcome will be the rate of hyperglycaemia or ketoacidodis requiring treatment. Secondary outcomes will include neonatal rates of respiratory morbidity, hypoglycaemia, and sepsis, and maternal infectious morbidity.

Interventions

A single dose of betamethasone (as Celestone Chronodose (R)) 0.2mg/kg ultrasound-estimated fetal weight, administered by a maternal fetal medicine specialist by ultrasound-guided injection into the fetal thigh between 34w0d and 36w4d gestation

Sponsors

Women and Newborns Health Service
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Pregnant woman Pregestational type 1 or type 2 diabetes mellitus Delivery indicated between 34w0d and 36w6d gestation Treating clinician feels that antenatal corticosteroid therapy is indicated Fetus accessible for intramuscular injection

Exclusion criteria

Age < 18 years Unable to provide informed consent Known fetal anomaly Multiple pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026